IDiyas

For the Inventor, By the Inventor

Wakefield, MA, United States of America

John Ryan Kerrigan

USPTO Granted Patents = 12 

 

Average Co-Inventor Count = 8.5

ph-index = 3

Forward Citations = 46(Granted Patents)


Company Filing History:

goldMedal12 out of 3,923 
 
Novartis Ag
 patents

Years Active: 2014-2025

Loading Chart...
Loading Chart...
12 patents (USPTO):
1. 12252482 - Pyrazolopyridine derivatives and uses thereof (2025-03-18),
2. 12172984 - Pyrazolopyridine derivatives and uses thereof (2024-12-24),
3. 12103919 - 3-(5-oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof (2024-10-01),
4. 11787785 - Pyrazolopyridine derivatives and uses thereof (2023-10-17),
5. 11566022 - 3-(5-methoxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof (2023-01-31),
6. 11229648 - 1,4-disubstituted pyridazine analogs thereof and methods for treating SMN-deficiency-related conditions (2022-01-25),
7. 10758533 - 1,4-disubstituted pyridazine analogs there of and methods for treating SMN-deficiency-related conditions (2020-09-01),
8. 10654828 - Indole derivatives and uses thereof (2020-05-19),
9. 10633350 - Diphenyl derivatives and uses thereof (2020-04-28),
10. 10195196 - 1,4-disubstituted pyridazine analogs there of and methods for treating SMN-deficiency-related conditions (2019-02-05),
11. 9545404 - 1,4-disubstituted pyridazine analogs there of and methods for treating SMN-deficiency-related conditions (2017-01-17),
12. 8729263 - 1,4-disubstituted pyridazine analogs there of and methods for treating SMN-deficiency-related conditions (2014-05-20),

Certainly! Here is an article about inventor John Ryan Kerrigan:

Title: Innovator Spotlight - John Ryan Kerrigan

Introduction:

John Ryan Kerrigan, a prolific inventor based in Wakefield, MA, has made significant contributions to the field of pharmaceuticals with his groundbreaking patents. With a total of 9 patents to his name, Kerrigan has been at the forefront of innovative research aimed at treating inherited blood disorders.

Latest Patents:

Kerrigan's most recent patents include "Pyrazolopyridine derivatives and uses thereof" and "3-(5-methoxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof". These patents focus on reducing Widely Interspaced Zinc Finger Motifs (WIZ) expression levels, inducing fetal hemoglobin (HbF) expression, and treating inherited blood disorders such as sickle cell disease and beta-thalassemia.

Career Highlights:

Currently affiliated with Novartis AG, a leading pharmaceutical company known for its innovative research and development efforts, John Ryan Kerrigan has been instrumental in advancing novel treatment options for patients with hemoglobinopathies. His expertise and dedication have led to the successful development of cutting-edge pharmaceutical compositions.

Collaborations:

In his professional journey, Kerrigan has collaborated closely with esteemed colleagues such as Natalie Alysia Dales and Gary O'Brien. Together, they have synergized their skills and knowledge to push the boundaries of pharmaceutical research and create impactful solutions for patients in need.

Conclusion:

John Ryan Kerrigan stands as a remarkable inventor whose work has the potential to revolutionize the treatment of inherited blood disorders. Through his inventive spirit and relentless pursuit of scientific excellence, Kerrigan continues to make significant strides in the field of pharmaceutical innovation, leaving a lasting impact on the healthcare industry.

If you need further assistance or more information, feel free to reach out!

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…